GlassScriptPhysician profile
Stephen David Jones
NPI 1720322688
$15,587.23
in general payments reported to CMS, 2019-2025
31 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,971 · 2022: $2,215 · 2023: $6,510 · 2024: $2,963 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,504 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,575 · Travel and Lodging: $299 · Education: $22.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,504.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,575.00 |
| Travel and Lodging | $298.92 |
| Education | $22.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,972.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,911.75 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,340.92 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $950.48 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neuronetics, INC. | $751.10 | 2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $626.07 | 2021-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $596.90 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $499.22 | 2023-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $495.75 | 2021-2022 | |
| Corium, LLC | $424.49 | 2022-2024 | Azstarys |
| Tris Pharma INC | $347.81 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Vanda Pharmaceuticals INC. | $328.35 | 2021-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $311.96 | 2022-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $284.93 | 2021-2025 | Trintellix |
| Lundbeck LLC | $266.63 | 2021-2023 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $229.65 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $205.68 | 2022-2023 | Ingrezza |
| Bausch Health US, LLC | $201.23 | 2021-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $148.78 | 2023-2025 | Auvelity |
| Validus Pharmaceuticals LLC | $133.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $107.31 | 2024 | |
| Idorsia Pharmaceuticals US INC | $91.78 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $89.22 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $85.00 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $67.25 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $29.14 | 2021-2022 | |
| Janssen Biotech, INC. | $24.89 | 2023 | |
| Neos Therapeutics, LP | $19.79 | 2021 | |
| Acadia Pharmaceuticals INC | $18.23 | 2023 | Daybue |
| Merck Sharp & Dohme LLC | $14.39 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.